| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Margetuximab-cmkb (Margenza) | 2025-10-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Datopotamab deruxtecan-dlnk (Datroway) | 2025-10-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Ado-trastuzumab emtansine (Kadcyla) | 2025-10-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Docetaxel (Taxotere) | 2025-10-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Pertuzumab (Perjeta) | 2025-10-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Lumasiran (Oxlumo) | 2025-10-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Revakinagene taroretcel-lwey (Encelto) | 2025-10-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Chelation Therapy for Off-Label Uses | 2025-10-01 |
| BCBS Highmark Penn Medicare Advantage | Routine Foot Care | 2025-10-01 |
| BCBS Highmark Penn Medicare Advantage | Speech - Language Pathology Services: Communication Disorders | 2025-10-01 |